HRV Pharma has launched RIKO™, India’s first AI-native pharmaceutical operating system — a self-learning reasoning engine built in-house on millions of proprietary decisions drawn from seven years of operating history.
The platform is trained on real operational workflows across sourcing, manufacturing, regulatory, quality and commercial functions, generated within a network of more than 50 FDA and EU-GMP certified manufacturing partners and customers in 55 countries — not on publicly available data alone.
How RIKO™ Works
Ten federated reasoning models retrain continuously through a shared contextual architecture, weighing multiple parameters at once before a sourcing commitment or licensing decision is finalised:
- Chemistry risk and nitrosamine potential
- Supplier reliability and manufacturing capability
- Regulatory history and inspection record
- Commercial alignment and live market signals
Early Results
- 94% predictive accuracy in flagging nitrosamine-related risk patterns during early assessment.
- 85% reduction in supplier qualification timelines, compressing four-to-eight-week cycles while retaining human sign-off.
- Under two seconds to assess an inbound enquiry, match it to suitable suppliers and prioritise it.
What It Changes
For manufacturing partners, slow paperwork-heavy qualification is replaced by a faster, more transparent path to being matched against live inquiries. For customers and licensing partners, quality, compliance and supply risks surface before agreements are signed — not during an audit or after a product reaches the market.
Competitive advantage in pharmaceuticals has traditionally been measured in manufacturing scale and geographic reach. RIKO™ reflects a different position: the industry’s most valuable asset is accumulated operational intelligence, and that is what takes years to build.
